诚达药业(301201)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

301201 诚达药业

已收盘 03-27 15:00:00

{"stockData":{"symbol":"301201","market":"SZ","secType":"STK","nameCN":"诚达药业","latestPrice":20.06,"timestamp":1743058980000,"preClose":19.68,"halted":0,"volume":1844860,"delay":0,"changeRate":0.0193,"floatShares":87193799,"shares":155000000,"eps":0.4537,"marketStatus":"已收盘","change":0.38,"latestTime":"03-27 15:00:00","open":19.62,"high":20.06,"low":19.15,"amount":36356900,"amplitude":0.0462,"askPrice":20.06,"askSize":17,"bidPrice":20.03,"bidSize":53,"shortable":0,"etf":0,"ttmEps":0.4537,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1743125400000},"marketStatusCode":5,"adr":0,"adjPreClose":19.68,"symbolType":"stock","openAndCloseTimeList":[[1743039000000,1743046200000],[1743051600000,1743058800000]],"highLimit":21.65,"lowLimit":17.71,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":154713824,"isCdr":false,"pbRate":1.36,"roa":"--","peRate":44.214238,"roe":"1.8%","epsLYR":0.5881,"committee":-0.410714,"marketValue":3104000000,"turnoverRate":0.0212,"status":0,"floatMarketCap":1749000000},"requestUrl":"/m/hq/s/301201","defaultTab":"news","newsList":[{"id":"2518621160","title":"3月10日诚达药业发生1笔大宗交易 成交金额416.01万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518621160","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518621160?lang=zh_cn&edition=full","pubTime":"2025-03-10 17:01","pubTimestamp":1741597292,"startTime":"0","endTime":"0","summary":"证券之星消息，3月10日诚达药业发生大宗交易，交易数据如下：大宗交易成交价格19.81元，相对当日收盘价折价1.98%，成交21万股，成交金额416.01万元，买方营业部为东兴证券股份有限公司成都都江堰市彩虹大道证券营业部，卖方营业部为财通证券股份有限公司深圳后海滨路证券营业部。近三个月该股共发生3笔大宗交易，合计成交6500.0手，折价成交3笔。截至2025年3月10日收盘，诚达药业报收于20.21元，上涨1.05%，换手率1.97%，成交量1.72万手，成交额3493.95万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031000022404.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301201","BK0239"],"gpt_icon":0},{"id":"2517106615","title":"诚达药业3月7日现1笔大宗交易 成交金额411.6万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517106615","media":"新浪证券-红岸工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517106615?lang=zh_cn&edition=full","pubTime":"2025-03-07 17:01","pubTimestamp":1741338060,"startTime":"0","endTime":"0","summary":"　　3月7日，诚达药业收跌2.25%，收盘价为20.00元，发生1笔大宗交易，合计成交量21万股，成交金额411.6万元。　　进一步统计，近3个月内该股累计发生2笔大宗交易，合计成交金额为872.75万元。该股近5个交易日累计上涨1.21%，主力资金合计净流出1577.47万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2025-03-07/doc-inenvmwk9838002.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["301201","BK0239"],"gpt_icon":0},{"id":"2516675202","title":"诚达药业：公司尚未开展AI制药领域相关业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2516675202","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516675202?lang=zh_cn&edition=full","pubTime":"2025-03-04 21:00","pubTimestamp":1741093218,"startTime":"0","endTime":"0","summary":"证券之星消息，诚达药业(301201)03月04日在投资者关系平台上答复投资者关心的问题。投资者：公司在AI生物制药这个领域有什么布局吗？诚达药业董秘：尊敬的投资者您好，公司将积极关注AI制药等新兴技术的发展与应用，不断探索新兴技术在公司业务、管理等方面的应用。但截止目前，公司尚未开展AI制药领域相关业务。应披露信息请以公司公告为准，请谨防概念炒作并注意投资风险。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030400039033.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1191","01477","BK0239","301201"],"gpt_icon":0},{"id":"2510835781","title":"诚达药业最新公告：通过FDA现场检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2510835781","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510835781?lang=zh_cn&edition=full","pubTime":"2025-02-10 16:59","pubTimestamp":1739177966,"startTime":"0","endTime":"0","summary":"诚达药业公告称，公司于2024年11月接受了美国FDA的cGMP现场检查，检查范围涵盖质量体系、物料、生产、包装与标签、设备设施、实验室控制六大系统。近日，公司收到FDA签发的现场检查报告，以NAI结果顺利通过检查。这表明公司在药品cGMP质量管理体系和生产环境设施等方面符合FDA要求，对公司拓展国际市场和提升核心竞争力产生积极影响。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025021000021229.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301201","BK0239"],"gpt_icon":0},{"id":"2510880581","title":"诚达药业(301201.SZ)通过FDA现场检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2510880581","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510880581?lang=zh_cn&edition=full","pubTime":"2025-02-10 16:08","pubTimestamp":1739174900,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诚达药业(301201.SZ)公告，公司于2024年11月11日至15日接受了来自美国食品药品监督管理局(简称“FDA”)的cGMP(现行药品生产质量管理规范)现场检查，检查范围涵盖质量体系、物料、生产、包装与标签、设备设施、实验室控制六大系统。近日，公司收到FDA签发的现场检查报告(EIR)，该报告表明公司已通过本次现场检查。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1247732.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301201","BK0239"],"gpt_icon":0},{"id":"2504412472","title":"诚达药业（301201）1月17日主力资金净卖出472.39万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2504412472","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2504412472?lang=zh_cn&edition=full","pubTime":"2025-01-20 09:21","pubTimestamp":1737336101,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2025年1月17日收盘，诚达药业报收于18.34元，下跌3.98%，换手率2.84%，成交量2.48万手，成交额4526.77万元。近5日资金流向一览见下表：诚达药业融资融券信息显示，融资方面，当日融资买入503.16万元，融资偿还601.05万元，融资净偿还97.89万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025012000002906.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301201","BK0239"],"gpt_icon":0},{"id":"2503936189","title":"诚达药业：预计2024年全年归属净利润亏损2100万元至2900万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503936189","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503936189?lang=zh_cn&edition=full","pubTime":"2025-01-16 20:02","pubTimestamp":1737028929,"startTime":"0","endTime":"0","summary":"证券之星消息，诚达药业发布业绩预告，预计2024年全年归属净利润亏损2100万元至2900万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025011600035080.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301201"],"gpt_icon":0},{"id":"2503969195","title":"诚达药业(301201.SZ)发预亏 2024年度净亏损2100万元–2900万元 同比由盈转亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2503969195","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503969195?lang=zh_cn&edition=full","pubTime":"2025-01-16 18:32","pubTimestamp":1737023533,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诚达药业(301201.SZ)披露2024年度业绩预告，该公司预计报告期归属于上市公司股东的净亏损2100万元–2900万元，扣除非经常性损益后的净亏损5000万元–6000万元，同比由盈转亏。报告期营业收入同比降幅约16%-27%。其中：原料药业务销售收入同比下降约33%，主要系产品药用级左卡尼汀因2023年客户超量备货，报告期需求回落导致;公司CDMO业务订单减少，销售收入下降。此外，公司研发费用约9000万至9800万，较上年增加约6600多万。预计公司报告期非经常性损益对净利润的影响金额约3000万元，主要为计入当期损益的政府补助及现金管理投资收益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1238826.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301201","BK0239"],"gpt_icon":0},{"id":"2503969286","title":"诚达药业预计2024年1-12月净利润亏损2,100万元至2,900万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503969286","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503969286?lang=zh_cn&edition=full","pubTime":"2025-01-16 18:30","pubTimestamp":1737023459,"startTime":"0","endTime":"0","summary":"诚达药业公告称，预计2024年1-12月归属于上市公司股东的净利润亏损:2,100万元至2,900万元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/01/16183047522596.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["301201"],"gpt_icon":0},{"id":"2503596909","title":"诚达药业最新公告：2024年度预计净利润亏损2100万元–2900万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503596909","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503596909?lang=zh_cn&edition=full","pubTime":"2025-01-16 18:19","pubTimestamp":1737022797,"startTime":"0","endTime":"0","summary":"诚达药业发布2024年度业绩预告，预计2024年归属于上市公司股东的净利润亏损2100万元–2900万元，上年同期盈利9098万元。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025011600031642.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301201"],"gpt_icon":0},{"id":"2502494066","title":"诚达药业(301201.SZ)：目前在手订单情况良好","url":"https://stock-news.laohu8.com/highlight/detail?id=2502494066","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2502494066?lang=zh_cn&edition=full","pubTime":"2025-01-09 15:09","pubTimestamp":1736406576,"startTime":"0","endTime":"0","summary":"格隆汇1月9日丨诚达药业在投资者关系活动上表示，公司目前在手订单情况良好；公司持续加大市场开发力度，完善市场开发网络，紧跟市场需求加强自有项目的储备以应对市场的需求。公司原料药业务布局中枢神经药物、心血管药物、糖尿病药物、抗炎药物、重症肌无力药物、妇科用药等多个适应症。达格列净原料药于2024年11月通过了CDE审批，进一步丰富公司的产品线。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/01/09150947290593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","301201"],"gpt_icon":0},{"id":"2502503878","title":"【机构调研记录】安信基金调研沃格光电、诚达药业","url":"https://stock-news.laohu8.com/highlight/detail?id=2502503878","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2502503878?lang=zh_cn&edition=full","pubTime":"2025-01-09 08:03","pubTimestamp":1736380983,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及1月8日披露的机构调研信息，安信基金近期对2家上市公司进行了调研，相关名单如下：1）沃格光电 个股亮点：公司产品有UTG超满柔性玻璃，可用于折叠手机、折叠平板折叠笔电、留能字戴曲面屏、超浦电子书等。旗下最近一年表现最佳的公募基金产品为安信深圳科技LOF，最新单位净值为1.15，近一年增长28.69%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025010900006014.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301201","BK0214","603773","BK0239"],"gpt_icon":0},{"id":"2501473447","title":"诚达药业：1月8日接受机构调研，安信基金参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2501473447","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2501473447?lang=zh_cn&edition=full","pubTime":"2025-01-08 19:01","pubTimestamp":1736334082,"startTime":"0","endTime":"0","summary":"证券之星消息，2025年1月8日诚达药业发布公告称公司于2025年1月8日接受机构调研，安信基金刘潇参与。诚达药业主营业务：跨国制药企业及医药研发机构提供关键医药中间体、原料药CDMO研发生产服务,以及左旋肉碱系列产品、原料药的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025010800033200.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301201","BK0239"],"gpt_icon":0},{"id":"2500162322","title":"诚达药业最新公告：医药中间体项目和原料药项目结项","url":"https://stock-news.laohu8.com/highlight/detail?id=2500162322","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2500162322?lang=zh_cn&edition=full","pubTime":"2025-01-03 17:10","pubTimestamp":1735895415,"startTime":"0","endTime":"0","summary":"诚达药业公告，公司募集资金投资项目“医药中间体项目”和“原料药项目”已竣工，达到预定可使用状态，满足结项条件。公司首次公开发行股票募集资金净额为16.21亿元，超募资金为11.08亿元。截至2024年12月31日，“医药中间体项目”累计投入募集资金1.55亿元，投入进度100%；“原料药项目”累计投入募集资金1.60亿元，投入进度89.40%。结项后，公司将保留募集资金专用账户，待支付工程建设尾款及质保金等将继续存放于募集资金专用账户。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025010300030315.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK1515","09939","BK0239","BK1574","BK1161","301201"],"gpt_icon":0},{"id":"2492932183","title":"诚达药业：财通证券投资者于12月17日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2492932183","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2492932183?lang=zh_cn&edition=full","pubTime":"2024-12-17 18:33","pubTimestamp":1734431589,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年12月17日诚达药业发布公告称财通证券华挺 赵千于2024年12月17日调研我司。诚达药业主营业务：跨国制药企业及医药研发机构提供关键医药中间体、原料药CDMO研发生产服务,以及左旋肉碱系列产品、原料药的研发、生产和销售。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121700032333.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601108","BK0276","BK0239","301201"],"gpt_icon":0},{"id":"2490460838","title":"诚达药业(301201.SZ)完成回购2.1%股份 耗资5706.16万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490460838","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2490460838?lang=zh_cn&edition=full","pubTime":"2024-12-11 16:41","pubTimestamp":1733906515,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诚达药业(301201.SZ)公告，截至本公告披露日，公司通过股份回购专用证券账户以集中竞价交易方式累计回购公司股份数量324.47万股，占公司当前总股本的2.10%(以公司当前总股本154,713,824股计算)，最高成交价为22.21元/股，最低成交价为14.63元/股，成交总金额为5706.16万元(不含交易费用)，本次回购股份方案实施完毕。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1223477.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301201","BK0239"],"gpt_icon":0},{"id":"2490130723","title":"诚达药业：上海睿华资产管理有限公司投资者于12月9日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2490130723","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2490130723?lang=zh_cn&edition=full","pubTime":"2024-12-09 19:32","pubTimestamp":1733743976,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年12月9日诚达药业发布公告称上海睿华资产管理有限公司朱崇玮于2024年12月9日调研我司。公司左旋肉碱系列产品出口全球30多个国家，品质稳定，拥有良好的国际知名度，已成为全球左旋肉碱主要供应商之一。目前公司左旋肉碱产品销售价格相对稳定，较最低行情已略有好转，后续相关产品价格走势存仍存在一定的不确定性。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120900027016.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1258","09983","BK0239","BK1542","BK1583","BK1229","301201"],"gpt_icon":0},{"id":"2490718823","title":"美生物安全法案“生变”，CRO概念大举反攻，药明系嗨了！","url":"https://stock-news.laohu8.com/highlight/detail?id=2490718823","media":"格隆汇","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2490718823?lang=zh_cn&edition=full","pubTime":"2024-12-09 12:10","pubTimestamp":1733717419,"startTime":"0","endTime":"0","summary":"行业悲观预期或好转","market":"sg","thumbnail":"https://img3.gelonghui.com/25d53-cb9c4747-fd5c-4169-a43e-056e33d68b09.jpg?guru_height=718&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/25d53-cb9c4747-fd5c-4169-a43e-056e33d68b09.jpg?guru_height=718&guru_width=1280"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/1449943","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["LU2039709279.SGD","LU0823426480.USD","LU1794554557.SGD","LU0456827905.SGD","LU0043850808.USD","02268","BK0028","LU1997245177.USD","LU0327786744.USD","BK0086","LU2488822045.USD","LU1880383366.USD","BK1141","LU0456842615.SGD","LU0856984785.SGD","300149","LU0823426308.USD","LU0348735423.USD","000710","BK0042","BK0077","LU1242518931.SGD","LU0052750758.USD","LU0307460666.USD","LU2242644610.SGD","LU1688375341.USD","SG9999014674.SGD","02359","301201","LU0572944931.SGD","LU0051755006.USD","LU0359202008.SGD","603259","BK1583","BK1521","LU0320764599.SGD","LU1046422090.SGD","LU0348825331.USD","BK0102","LU0516422366.SGD","BK0081","LU0456846285.SGD","SG9999002562.SGD","LU0819121731.USD","BK1576","LU2045819591.USD","LU0359201612.USD","NDAA","BK0216"],"gpt_icon":1},{"id":"2485404827","title":"诚达药业：因自身经营需要 股东前海晟泰投资拟减持不超638.49万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2485404827","media":"中国财富通","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2485404827?lang=zh_cn&edition=full","pubTime":"2024-11-22 12:10","pubTimestamp":1732248606,"startTime":"0","endTime":"0","summary":"中国财富通11月22日 - 诚达药业（301201）公告称，持有公司股份17,391,840股（占本公司剔除回购专户股份数后总股本比例11.48%）的股东深圳前海晟泰投资企业（有限合伙），计划在本公告披露之日起15个交易日后的3个月内（2024年12月16日至2025年3月15日），以大宗交易方式减持本公司股份不超过6,384,943股（占本公司剔除回购专户股份数后总股本比例4.22%）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=EQRsFpITDNQ%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","301201"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1743065199686,"stockEarnings":[{"period":"1week","weight":-0.0277},{"period":"1month","weight":-0.0474},{"period":"3month","weight":-0.057},{"period":"6month","weight":0.0197},{"period":"1year","weight":-0.0419},{"period":"ytd","weight":-0.0248}],"compareEarnings":[{"period":"1week","weight":-0.0168},{"period":"1month","weight":-0.0013},{"period":"3month","weight":-0.0086},{"period":"6month","weight":0.0911},{"period":"1year","weight":0.1112},{"period":"ytd","weight":0.0051}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"诚达药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"14654人(较上一季度减少1.65%)","perCapita":"5950股","listingDate":"2022-01-20","address":"浙江省嘉兴市嘉善县惠民街道黄河路36号","registeredCapital":"15471万元","survey":"　　诚达药业股份有限公司主要致力于为跨国制药企业及医药研发机构提供关键医药中间体、原料药CDMO服务，并从事左旋肉碱系列产品的研发、生产和销售。公司主要产品及服务是预临床及临床阶段新药CDMO服务、已上市药物CDMO服务、仿制药中间体CDMO服务、食品添加剂、饲料添加剂、原料药。公司是国内最早实现左旋肉碱系列产品产业化的企业之一，也是全球左旋肉碱主要供应商之一。产品产业链齐全，包括食品添加剂、饲料添加剂、原料药，产品出口全球30多个国家和地区。","listedPrice":72.69},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诚达药业(301201)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诚达药业(301201)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诚达药业,301201,诚达药业股票,诚达药业股票老虎,诚达药业股票老虎国际,诚达药业行情,诚达药业股票行情,诚达药业股价,诚达药业股市,诚达药业股票价格,诚达药业股票交易,诚达药业股票购买,诚达药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诚达药业(301201)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诚达药业(301201)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}